REFERENCES

REFERENCES

Ascherio, A., & Schwarzschild, M. A. (2016). The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet Neurology, 15(12), 1257-1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Barker, R. A., Barrett, J., & McGowan, J. (2017). The challenge of translating stem cell therapy for Parkinson’s disease. The Lancet Neurology, 16(8), 703-711. https://doi.org/10.1016/S1474-4422(17)30243-0 

Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284-2303. https://doi.org/10.1016/S0140-6736(21)00218-X 

Bloem, B. R., de Vries, N. M., & Ebersbach, G. (2015). Nonpharmacological treatments for patients with Parkinson's disease. Movement Disorders, 30(11), 1504-1520. https://doi.org/10.1002/mds.26364 

Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197-211. 

Dauer, W., & Przedborski, S. (2003). Parkinson's Disease: Mechanisms and Models. Neuron, 39(6), 889-909. 

Dick, F. D., De Palma, G., Ahmadi, A., Osborne, A., & Seaton, A. (2007). Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occupational and Environmental Medicine, 64(10), 666-672. https://doi.org/10.1136/oem.2006.028738 

Dickson, D. W. (2018). Neuropathology of Parkinson disease. Parkinsonism & Related Disorders, 46(Suppl 1), S30-S33. 

Dorsey, E. R., Bloem, B. R., Okun, M. S., & Lang, A. E. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson’s Disease, 8(s1), S3-S8. https://doi.org/10.3233/JPD-181474 

Espay, A. J., Kalia, L. V., & Gan-Or, Z. (2018). How much of Parkinson's disease is genetically determined? Parkinsonism & Related Disorders, 46, S73-S77. https://doi.org/10.1016/j.parkreldis.2017.07.013 

Fox, S. H., Katzenschlager, R., Lim, S. Y., Barton, B., de Bie, R. M., Seppi, K., & Coelho, M. (2018). International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Movement Disorders, 33(8), 1248-1266. https://doi.org/10.1002/mds.27372 

Goldman, S. M., & Tanner, C. M. (2011). Etiology of Parkinson's Disease. In Parkinson’s Disease and Movement Disorders (6th ed.). Wolters Kluwer Health. 

Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368-376. https://doi.org/10.1136/jnnp.2007.131045 

Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912.

Lang, A. E., & Espay, A. J. (2021). Disease-modifying therapies for Parkinson disease: Challenges and future directions. JAMA, 325(12), 1117-1118. https://doi.org/10.1001/jama.2021.1639 

Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., ... & Tanner, C. M. (2018). Prevalence of Parkinson's disease across North America. NPJ Parkinson's Disease, 4, 21.

Marras, C., & Tanner, C. M. (2012). Epidemiology of Parkinson’s disease. In Movement Disorders (5th ed.). Lippincott Williams & Wilkins. 

Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012). Parkinson's disease. Subcellular Biochemistry, 65, 1-52.

Oertel, W. H. (2017). Recent advances in treating Parkinson’s disease. F1000Research, 6, 260. https://doi.org/10.12688/f1000research.10453.1 

Phillips, K. (2024). Parkinson Disease [PowerPoint slides]. Department of Neuroscience, Virginia Tech. 

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.

Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014). The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disorders, 29(13), 1583-1590. https://doi.org/10.1002/mds.25945 

Ross, G. W., & Petrovitch, H. (2001). Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs & Aging, 18(11), 797-806. https://doi.org/10.2165/00002512-200118110-00004 

Schapira, A. H. V., & Jenner, P. (2011). Etiology and pathogenesis of Parkinson’s disease. Movement Disorders, 26(6), 1049-1055.

Tabrizi, S. J., & Simon, D. K. (2020). Pathophysiology of Parkinson’s disease: Recent advances and therapeutic strategies. Journal of Clinical Investigation, 130(5), 2141-2149. https://doi.org/10.1172/JCI136537 

IMAGES

Figure 1- Aetiology

Parkinson Disease Aetiology. (2024). Created using Microsoft Copilot with the prompt “Parkinson Disease Aetiology.”

Figure 2- Clinical Presentation

Parkinson Disease Clinical Presentation. (2024). Created using Microsoft Copilot with the prompt “Parkinson Disease Clinical Presentation.”

Figure 3- Treatments and Outlooks

Parkinson Disease Treatment and Outlooks. (2024). Created using Microsoft Copilot with the prompt “Parkinson Disease Treatment and Outlooks.”

Figure 4- Epidemiology

Parkinson Disease Epidemiology. (2024). Created using Microsoft Copilot with the prompt “Parkinson Disease Epidemiology.”

Figure 5- Looking Ahead

Parkinson Disease Looking Ahead. (2024). Created using Microsoft Copilot with the prompt “Parkinson Disease Looking Ahead.”